Clinical trial to Compare the efficacy of two different doses of sugammadex for reversal of vecuronium induced neuromuscular blockage in patients posted for elective surgeries under general anesthesia

Comparision of the efficacy of two different doses of sugammadex for reversal of vecuronium induced neuromuscular blockage in patients posted for elective surgeries under general anesthesia - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2024/08/071853

Enrollment

Registered

2024-08-02

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: 8- Other Procedures

Interventions

Intervention1: Inj.Sugammadex 1mg/kg: Compare efficacy of reversal by Inj.Sugammadex dose 1mg/kg with 2mg/kg in vecuronium induced neuromuscular blockage after T2 appearance on TOF Control Interventio

Eligibility

Inclusion criteria

Inclusion criteria: 1 Age 18 to 60 years 2 ASA grade 1 to 3 3 schedule for elective surgery under general anesthesia 4 Surgery duration less than 2 hours 5 BMI less than30

Exclusion criteria

Exclusion criteria: Suspected difficult intubation Significant hepatic and renal dysfunction Any suspected neuromuscular disorder Known or suspected family history of malignant hyperthermia Lactating or pregnant female

Design outcomes

Primary

Measure	Time frame
To compare clinical recovery profile of two different dose of sugammadex in terms of time require for spontaneous eye opening, adequate tidal volume (5ml/kg) , hand grip for 5 seconds and time requires for extubation. Timepoint: At baseline,Immediate after Inj.sugammadex and after 5min,10min,15min,30min,60min,90 min,120min after Inj.sugammadex	—

Secondary

Measure	Time frame
1. To compare the hemodynamic changes(Mean arterial pressure, Heart rate) after Inj. sugammadex 2. Side effects (If any) after Inj. sugammadex in both groups. Timepoint: At baseline,Immediate after Inj.sugammadex & after 5min,10min,15min,30min,60min,90 min,120min after Inj.sugammadex	—

Countries

India

Contacts

Public ContactDr Komal Shah

GMC Bhavnagar gujarat

shah.komal212@gmail.com9427215252

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026